From Medscape, August 8th 2023. Inhaling a pleasant aroma during sleep has been linked to an improvement in memory, small-scale early research suggests. Researchers randomly assigned 43 older adults, aged 60 – 85 years, to receive either nightly exposure to essential oil scents delivered via a diffuser (n = 20; mean [SD] age, 70.1 [6.6]…
Ketogenic diet in RRMS
Study suggests benefits may be long lasting Following a ketogenic diet for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study has shown. The research, Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial…
Oxygen for brain injuries – can it help patients?
Inhaling oxygen while learning a motor task helped healthy people learn more quickly and effectively, raising hopes for neurorehabilitation Scientists studying the impact of oxygen supplementation on motor learning have found a promising treatment that could help patients who have experienced neurological trauma recover old skills. “A simple and easy to administer treatment with 100%…
Epilepsy associated with CDKL5 Deficiency Disorder
European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder 31 July 2023: Marinus Pharmaceuticals announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to…
AI enhances clinical decision-making in radiology
AI solution will help improve patient outcomes by providing timely and accurate detection of critical abnormalities Milton Keynes University Hospital NHS Foundation Trust (MKUH) will use Qure’s qER for automating the detection of critical and life-threatening abnormalities in head CT scans, including intracranial haemorrhages (ICH) caused by trauma, accidents or strokes. It is an FDA…
Positive CHMP opinion for multiple sclerosis biosimilar natalizumab
July 24, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorisation for first-of-a-kind biosimilar natalizumab developed by Polpharma Biologics. The authorisation covers treatment as a single disease-modifying…
SPRAVATO® for adults with treatment-resistant major depressive disorder
Findings presented at Royal College of Psychiatrists International Congress (RCPsych 2023) confirm the importance of SPRAVATO® as a therapeutic option for adults with treatment-resistant major depressive disorder in patients with 2 and >3 prior treatment failures.1 10 July 2023: The Janssen Pharmaceutical Companies of Johnson & Johnson announced further findings from the ESCAPE-TRD study. Data…
Improvements in treatment of intracranial aneurysms
Meta-analysis shows fewer complications and higher occlusion rates for ruptured wide-neck intracranial aneurysms, using Rapid Medical’s COMANECI™ Embolisation Assist Device 19 July 2023: Rapid Medical™, developer of advanced neurovascular devices, has announced new clinical data showing significant advantages of its novel COMANECI™ embolisation assist device over established techniques to treat ruptured wide-neck intracranial aneurysms. A recent meta-analysis…
Subcutaneous Ocrevus injection – OCARINA II trial results
Phase III trial results could strengthen Ocrevus’s position in multiple sclerosis GlobalData, 19th July 2023: Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice yearly for ten minutes, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive…
